Merck KGaA nears $3.5bn deal for SpringWorks
Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.
Therapy Area
FDA free to pursue semaglutide compounders after latest court ruling
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Veraxa to go public in $1.6bn SPAC deal with Voyager
Synthetic hormones and the future of contraception
Boehringer to expand oncology presence with $572m Tessellate Bio deal
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
